Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug ...

The Danish pharmaceutical giant is putting up ... keep the alliance from spreading into areas where Ascendis’s internal pipeline already has product candidates. But Novo Nordisk has exclusive ...

BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong ...

Ascendis Pharma (ASND) Company Description: Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a ...

In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon ...

Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.

In August, the FDA approved Ascendis Pharma’s Yorvipath ... different groups of users across healthcare and pharma companies. The Septerna pipeline includes two preclinical negative allosteric ...

In this article, we are going to take a look at where Ascendis Pharma A/S (NASDAQ ... stock reduces the further down the development pipeline a firm is. Drugs that are in late stage clinical ...

Plus: How AI can help cancer patients avoid unnecessary chemotherapies and make it easier to understand your dental X-rays.

The specialty pharmaceutical pipeline is expanding with innovative therapies, including cell and gene therapies, biosimilars, and treatments for rare diseases and complex disorders. Recent drug ...

Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...